Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.
J A Kemp
We are one of the largest UK and European Patent and Trade Mark Attorney firms, with offices in London, Oxford, Cambridge and Munich.
The breadth and depth of our technical knowledge relevant to patents is outstanding, with over 50 science and technology graduates in the firm including over 30 PhDs. No area of science or technology is outside our scope.
Karma Oncology is a specialized oncology clinical development organisation headquartered in Scotland with offices in Ireland, Netherlands and USA.
Karma offers a bespoke service, from the preparation of clinical development plans through design, set-up & execution of clinical trials. Our expertise includes the design and execution of autologous and CAR-T cell therapy studies in Europe and North America.
The company was founded in 2012 by Dr Karen J Williams, who, while working as a Sponsor, had become increasingly frustrated by the inevitable constraints and rigidity smaller companies can experience being lost and forgotten in larger CRO’s. Utilizing her 30 years’ experience in pharma and CRO industries, Dr Williams started Karma Oncology to ensure smaller biotech’s get the service and attention they deserve. She has surrounded herself with like-minded professionals and built a team, who, like herself have a passion for this work and are Knowledgeable, Adaptable, Reliable, Motivated and Accountable.
Masters Speciality Pharma
Founded over 30 years ago, Masters Speciality Pharma is an international pharmaceutical company specialising in the distribution of unlicensed medicinal products to Physicians, Hospitals, Clinics, Government institutions and individual patients, providing access to essential life-saving treatments worldwide.
Masters is fully compliant with regulatory requirements in all jurisdictions enabling us to deliver tailored medical solutions to over 90 countries worldwide, and is trusted as a reliable source of pharmaceutical product
Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.
Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.
The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.
As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.
MediWales is the life science network and representative body for Wales. An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.
MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally.
metaLinear offers a fast track to highly validated drug targets and lead compounds, some of which will be available for licensing. Our focus is on antibiotics/antibiotic resistance. Our proven technology manipulates proteins inside living cells, reaching the >90% of biology inaccessible to siRNA or CAS/Crispr.
metaLinear was established in November 2016 and began operating from the Biohub at Alderley Park in Cheshire from March 2017. Operated by life science incubation specialist, The BioCity Group, Biohub supports the creation and growth of successful life science companies including Redx, Blueberry Therapeutics and the Anti-Microbial Research Centre.
MGB Biopharma is a private company based in Glasgow, Scotland and is backed by a syndicate of Scotland’s leading angel investor groups together with Scottish Enterprise. Antimicrobial drug resistance is recognised as a global public health concern with an urgent need for new antibacterial drug classes that are more effective than existing treatments. MGB is developing the first truly novel class of anti-infectives in over a decade that has the potential to treat infections of a number of the most important susceptible and resistant pathogens.
Our lead compound has shown strong bactericidal activity with quick onset of action against many strains of Gram-positive bacteria. It has completed pre-clinical development and progress into our phase 1 clinical study for the treatment of Clostridium difficile have been endorsed by the MHRA. Optimisation of a new formulation for intravenous administration and treatment of systemic Gram-positive infection is ongoing.
MGB has acquired exclusive rights to the proprietary minor groove binder platform, developed at the University of Strathclyde, Glasgow. This platform provides an opportunity to develop additional compounds with the potential to treat Gram-negative, viral, fungal and parasitic infections. MGB continues to work closely with Strathclyde University to develop the pipeline and is currently seeking partners to help maximise the value-creating opportunities from its broad platform.
Mironid is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signaling proteins.
Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and can be applied to a wide range of solid tumour types.
Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in Kansas City, USA.